IMIDomics and Bristol Myers Squibb Expand Long-Standing Partnership to Advance Immune-Mediated Inflammatory Disease Treatment Research and Development

SAN RAFAEL, Calif.–(BUSINESS WIRE)–IMIDomics, a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), announced today that it is expanding its strategic collaboration with Bristol Myers Squibb, a global biopharmaceutical company. This expanded partnership extends the existing relationship between the two companies, advancing their shared commitment to…
Click here to view original post